Anticipated Launch of Novel Molecules Will Drive Growth of the CNS Disease Market in Forecast Period

Friday 21 October 2011, Amsterdam

Anticipated Launch of Novel Molecules Will Drive Growth of the CNS Disease Market in Forecast Period

The global central nervous system (CNS) disorder therapeutics market is valued as $53.1 billion in 2010, grew from $36.8 billion in 2002 with a Compound Annual Growth Rate (CAGR) of 4.7%. Increasing geriatric populations all over the world along with increases in life expectancy are expected to increase the disease population of CNS disorders.

The product pipeline of the CNS disorder therapeutics market is promising, with many novel molecules at various stages of development, some with disease-modifying characteristics. The anticipated launch of late stage and novel molecules is expected to fulfill the unmet needs and drive the growth of the global CNS disorders therapeutics market in upcoming years. The product pipeline for multiple sclerosis (MS) has many orally administered novel molecules, and for Alzheimer’s disease the product pipeline has novel molecules such as bapineuzumab, solanezumab and BMS-708163 which target the underlying causes of the disease and thus may offer significant clinical benefits to the patients. The market for schizophrenia and bipolar disorder therapeutics is estimated to be driven by the anticipated launch of AZ-004 and other molecules such as cariprazine, zicronapine, and RG-1678 and aripiprazole depot injection. The continued uptake of non stimulants and anticipated launch of pipeline molecules is expected to have a significant impact on the ADHD therapeutics market. In the next few years the market will witness patent expiries of major drugs, however, the rapid uptake of new molecules is expected to stabilize the market’s decline and the market is expected to grow with a CAGR of 1.4% from 2010 to 2017 to reach $58.6 billion in 2017.

Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Market Contributed Almost 50% to Total CNS Disorder Therapeutic Market In 2010
The global CNS disease therapeutics market, consists of eleven indications that includes: Alzheimer’s disease, MS, Parkinson’s disease, diabetic neuropathy, insomnia, migraine, ADHD, major depressive disorder (MDD), schizophrenia, bipolar disorder and epilepsy, was valued as $53.1 billion in 2010. The MS, MDD and schizophrenia markets were the major revenue generators in the CNS disorder therapeutics market in 2010. The market for MS accounts for 14% of the total market, with the major revenue generator drugs being Avonex (interferon beta-1a), Rebif (interferon beta-1a), Tysabri (natalizumab) and Copaxone (glatiramer acetate). The MS market is estimated as $7,3754m in 2010. The market for MDD accounted for 16% of the total CNS disorder therapeutics market in 2010, with the major revenue generating drugs being Effexor (venlafaxine), Lexapro (escitalopram), Zoloft (sertraline), Pristiq (desvenlafaxine). The schizophrenia market was the major market in the CNS disorder therapeutics market in 2010, with about 19% of the total market. Zyprexa (olanzapine), Abilify (aripiprazole), Invega (paliperidone), Geodon (ziprasidone), and Seroquel (quetiapine) were the major revenue generators for the schizophrenia market in 2010.

The Alzheimer's disease and bipolar disorder therapeutics markets contributed 9% each to the global CNS disorder therapeutic market in 2010. The ADHD market contributed 8% while the migraine market contributed 6% to the total CNS therapeutic market in 2010. This was followed by the epilepsy market (6%) and the Parkinson’s disease and Insomnia market with 5% share each in 2010 global CNS therapeutic disorder market. The share of multiple sclerosis and Alzheimer’s disease therapeutics market is expected to increase significantly in future because of the strong product pipeline that comprises various novel molecules with disease modifying characteristics at various stages of clinical development.


Patent Expiries of Major Drugs Followed By Generic Erosion Will Affect CNS Disorder Therapeutics Market In Future

Thius study examined the CNS disorder therapeutics markets in the US, the top five countries of Europe (the UK, France, Germany, Italy and Spain) and Japan. The growth of CNS disorder therapeutics market will be affected due to recent and upcoming patent expiries. The patent of many blockbusters drugs such as Aricept (donepezil hydrochloride), Seroquel (quetiapine fumarate), Cymbalta (duloxetine HCl), Lyrica (pregabalin), Lunesta (eszopiclone), Maxalt (rizatriptan) and Zomig (zolmitriptan), Mirapex (pramipexole), Requip XL (ropinirole), Stalevo (carbidopa, levodopa and entacapone), Comtan (entacapone), Zyprexa (olanzapine), Geodon (ziprasidone HCl), Abilify (aripiprazole) and Saphris (asenapine), Lexapro (escitalopram oxalate) are either expired or is going to expire in forecast period. The patent expiries of these drugs followed by immediate entry of generic versions and subsequent increase in price pressure and competition will affect the CNS disorder therapeutics market in future.


About this new market study:
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major CNS disorder including Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, diabetic neuropathy, major depressive disorder (MDD), bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. The report also provides the share of generics in global CNS disorder therapeutics market as well as in each indication market. The report examines the global CNS disorder treatment usage patterns. In addition, the geographical distribution of CNS disorder and market across the US, the top five countries of Europe and in Japan. The report also includes insights into the CNS disorder R&D product pipeline and explores the competitive landscape including major players in CNS disease market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in CNS disorder therapeutics market.